Impact of the CHA

Left atrial appendage occlusion (LAAO) is an accepted strategy for cardioembolic events prevention in patients with non-valvular atrial fibrillation (AF) unsuitable for anticoagulation. However, uncertainties persist regarding the benefit of LAAO in highly-comorbid patients. The aim of this study was to assess the impact of the CHA160 patients who underwent LAAO were included and categorized into two groups according to their stroke risk (89 with CHAOver a median follow-up of 679 days, CHADespite increased long-term mortality in patients with CHA